{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:19:53Z","timestamp":1787066393548,"version":"build-2736575974"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To investigate the factors influencing the number of injections in myopic choroidal neovascularization as well as to identify the clinical features of patients who require a limited number of injections to inactive myopic choroidal neovascularization.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This retrospective study included 86 eyes (86 patients) affected by treatment-nai\u0308ve myopic choroidal neovascularization who were treated with pro re nata antivascular endothelial growth factor injections with a follow-up at 12 months. Patients underwent complete ophthalmic visits, optical coherence tomography and optical coherence tomography angiography both at baseline and at 12 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Overall, the mean age of the study population was 62 \u00b1 14 years. The mean number of intravitreal injections administered in the 12-month study period was 4.28 \u00b1 2.17. The multivariate analysis showed an association of baseline central macular thickness and best-corrected visual acuity (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.02 and 0.036, respectively) while the final factors related to injections number were subretinal fibrosis and final best-corrected visual acuity (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001 and\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.022, respectively). Patients who required one or two injections showed significant clinical differences in optical coherence tomography, optical coherence tomography angiography, and clinical parameters in comparison to patients who require more injections.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Baseline poorer best-corrected visual acuity and baseline higher central macular thickness are significantly associated with the need of more injections to stabilize the clinical picture in eyes affected by myopic choroidal neovascularization.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/iae.0000000000004605","type":"journal-article","created":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T17:00:22Z","timestamp":1752512422000},"page":"2271-2278","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["FACTORS INFLUENCING THE NUMBER OF ANTI-VEGF INJECTIONS IN MYOPIC CHOROIDAL NEOVASCULARIZATION"],"prefix":"10.1097","volume":"45","author":[{"given":"Niccol\u00f2","family":"Castellino","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, University of Catania, Catania, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8247-3666","authenticated-orcid":false,"given":"Giovanni","family":"Rubegni","sequence":"additional","affiliation":[{"name":"Department of Medicine, Ophthalmology Unit, Surgery and Neurosciences, University of Siena, Siena, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Brinkmann","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Klinikum Klagenfurt, Klagenfurt, Austria;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"M\u00fcller","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Klinikum Klagenfurt, Klagenfurt, Austria;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Boscia","sequence":"additional","affiliation":[{"name":"Department of Translational Biomedicine Neuroscience, University of Bari \u201cAldo Moro\u201d, Bari, Italy; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasquale","family":"Viggiano","sequence":"additional","affiliation":[{"name":"Department of Translational Biomedicine Neuroscience, University of Bari \u201cAldo Moro\u201d, Bari, Italy; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Oliva","family":"Grassi","sequence":"additional","affiliation":[{"name":"Department of Translational Biomedicine Neuroscience, University of Bari \u201cAldo Moro\u201d, Bari, Italy; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Ferraro","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of Catania, Catania, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Russo","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of Catania, Catania, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Boscia","sequence":"additional","affiliation":[{"name":"Department of Translational Biomedicine Neuroscience, University of Bari \u201cAldo Moro\u201d, Bari, Italy; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresio","family":"Avitabile","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of Catania, Catania, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Longo","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of Catania, Catania, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario Damiano","family":"Toro","sequence":"additional","affiliation":[{"name":"Public Health Department, Eye Clinic, University of Naples Federico II, Naples, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20251114","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.ophtha.2015.03.018","article-title":"Increasing prevalence of myopia in Europe and the impact of education","volume":"122","author":"Williams","year":"2015","journal-title":"Ophthalmology"},{"key":"R2-20251114","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1475-1313.2011.00884.x","article-title":"Worldwide prevalence and risk factors for myopia","volume":"32","author":"Pan","year":"2012","journal-title":"Ophthalmic Physiol Opt"},{"key":"R3-20251114","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.preteyeres.2018.12.001","article-title":"Posterior staphyloma in pathologic myopia","volume":"70","author":"Ohno-Matsui","year":"2019","journal-title":"Prog Retin Eye Res"},{"key":"R4-20251114","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/S0161-6420(83)80018-9","article-title":"Visual prognosis of disciform degeneration in myopia","volume":"90","author":"Hampton","year":"1983","journal-title":"Ophthalmology"},{"key":"R5-20251114","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1097\/IAE.0b013e318174417a","article-title":"Lacquer crack formation and choroidal neovascularization in pathologic myopia","volume":"28","author":"Ikuno","year":"2008","journal-title":"Retina"},{"key":"R6-20251114","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.preteyeres.2012.04.001","article-title":"Choroidal neovascularization in pathological myopia","volume":"31","author":"Neelam","year":"2012","journal-title":"Prog Retin Eye Res"},{"key":"R7-20251114","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.ajo.2015.07.004","article-title":"Spectral-domain optical coherence tomography of subretinal hyperreflective exudation in myopic choroidal neovascularization","volume":"160","author":"Bruy\u00e8re","year":"2015","journal-title":"Am J Ophthalmol"},{"key":"R8-20251114","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1136\/bjophthalmol-2016-309162","article-title":"Optical coherence tomography angiography of myopic choroidal neovascularisation","volume":"101","author":"Querques","year":"2017","journal-title":"Br J Ophthalmol"},{"key":"R9-20251114","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.1167\/iovs.17-23640","article-title":"Fluorescein leakage and optical coherence tomography features of choroidal neovascularization secondary to pathologic myopia","volume":"59","author":"Battaglia Parodi","year":"2018","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R10-20251114","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1097\/IAE.0000000000002005","article-title":"Application of optical coherence tomography angiography to assess anti-vascular endothelial growth factor therapy in myopic choroidal neovascularization","volume":"39","author":"Cheng","year":"2019","journal-title":"Retina"},{"key":"R11-20251114","doi-asserted-by":"crossref","first-page":"10435","DOI":"10.1038\/s41598-022-14287-7","article-title":"Morphological parameters of myopic choroidal neovascularization as predictive factors of anti-VEGF treatment response","volume":"12","author":"Castellino","year":"2022","journal-title":"Sci Rep"},{"key":"R12-20251114","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.ophtha.2013.10.023","article-title":"Radiance: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia","volume":"121","author":"Wolf","year":"2014","journal-title":"Ophthalmology"},{"key":"R13-20251114","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1016\/j.ophtha.2015.01.025","article-title":"Intravitreal aflibercept injection in patients with myopic choroidal neovascularization: the MYRROR study","volume":"122","author":"Ikuno","year":"2015","journal-title":"Ophthalmology"},{"key":"R14-20251114","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/j.ajo.2013.08.002","article-title":"Prognostic factors of eyes with na\u00efve subfoveal myopic choroidal neovascularization after intravitreal bevacizumab","volume":"156","author":"Yang","year":"2013","journal-title":"Am J Ophthalmol"},{"key":"R15-20251114","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ophtha.2017.07.014","article-title":"Treat-and-Extend versus monthly regimen in neovascular age-related macular degeneration: results with ranibizumab from the TREND study","volume":"125","author":"Silva","year":"2018","journal-title":"Ophthalmology"},{"key":"R16-20251114","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1007\/s00417-023-06271-2","article-title":"Treatment of myopic choroidal neovascularization: a network meta-analysis and review","volume":"262","author":"Glachs","year":"2024","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R17-20251114","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1097\/IAE.0000000000003856","article-title":"Predictive roles of quantitative optical coherence tomography angiography features in prognosis of myopic choroidal neovascularization","volume":"43","author":"Liu","year":"2023","journal-title":"Retina"},{"key":"R18-20251114","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1097\/IAE.0000000000001456","article-title":"Neovascularization secondary to high myopia imaged by optical coherence tomography angiography","volume":"37","author":"Bruy\u00e8re","year":"2017","journal-title":"Retina"},{"key":"R19-20251114","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1016\/j.ophtha.2009.11.003","article-title":"Long-term pattern of progression of myopic maculopathy: a natural history study","volume":"117","author":"Hayashi","year":"2010","journal-title":"Ophthalmology"},{"key":"R20-20251114","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1097\/IAE.0b013e31821800a4","article-title":"Intravitreal bevacizumab therapy on an as-per-needed basis in subfoveal choroidal neovascularization secondary to pathological myopia: 2-year outcomes of a prospective case series","volume":"31","author":"Iacono","year":"2011","journal-title":"Retina"},{"key":"R21-20251114","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.ajo.2012.11.021","article-title":"Angiographic and optical coherence tomography characteristics of recent myopic choroidal neovascularization","volume":"155","author":"Leveziel","year":"2013","journal-title":"Am J Ophthalmol"},{"key":"R22-20251114","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s00417-018-04214-w","article-title":"Effect of intravitreal injection of aflibercept or ranibizumab on chorioretinal atrophy in myopic choroidal neovascularization","volume":"257","author":"Sayanagi","year":"2019","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R23-20251114","doi-asserted-by":"crossref","first-page":"e0273613","DOI":"10.1371\/journal.pone.0273613","article-title":"Risk factors for myopic choroidal neovascularization-related macular atrophy after anti-VEGF treatment","volume":"17","author":"Bae","year":"2022","journal-title":"PLoS One"},{"key":"R24-20251114","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s00417-018-04205-x","article-title":"Vascular remodeling of choroidal neovascularization in older myopic patients treated with ranibizumab","volume":"257","author":"Cohen","year":"2019","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R25-20251114","first-page":"1132","article-title":"Three-year OCT predictive factors of disease recurrence in eyes with successfully treated myopic choroidal neovascularisation","volume":"106","author":"Borrelli","year":"2022","journal-title":"Br J Ophthalmol"},{"key":"R26-20251114","doi-asserted-by":"crossref","first-page":"3721","DOI":"10.1167\/iovs.09-3493","article-title":"Ocular risk factors for choroidal neovascularization in pathologic myopia","volume":"51","author":"Ikuno","year":"2010","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R27-20251114","doi-asserted-by":"crossref","first-page":"3834","DOI":"10.1167\/iovs.12-9811","article-title":"Morphologic analysis in pathologic myopia using high-penetration optical coherence tomography","volume":"53","author":"Maruko","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R28-20251114","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1016\/j.ophtha.2013.06.010","article-title":"Ranibizumab in myopic choroidal neovascularization: the 12-month results from the REPAIR study","volume":"120","author":"Tufail","year":"2013","journal-title":"Ophthalmology"},{"key":"R29-20251114","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1097\/IAE.0000000000001043","article-title":"Subretinal fibrosis after antivascular endothelial growth factor therapy in eyes with myopic choroidal neovascularization","volume":"36","author":"Ahn","year":"2016","journal-title":"Retina"},{"key":"R30-20251114","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1097\/IAE.0000000000002388","article-title":"Optical coherence tomography angiography features of subretinal fibrosis after myopic neovascularization","volume":"40","author":"Milani","year":"2020","journal-title":"Retina"},{"key":"R31-20251114","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1136\/bjophthalmol-2019-315763","article-title":"Risk factors for subretinal fibrosis after anti-VEGF treatment of myopic choroidal neovascularisation","volume":"105","author":"Xiao","year":"2021","journal-title":"Br J Ophthalmol"},{"key":"R32-20251114","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/j.oret.2022.06.009","article-title":"Long-term incidence and risk factors of macular fibrosis, macular atrophy, and macular hole in eyes with myopic neovascularization","volume":"6","author":"Cicinelli","year":"2022","journal-title":"Ophthalmol Retina"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000004605","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T15:00:49Z","timestamp":1763132449000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000004605"}},"subtitle":["A Multicenter Study"],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":32,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000004605","relation":{},"ISSN":["0275-004X","1539-2864"],"issn-type":[{"value":"0275-004X","type":"print"},{"value":"1539-2864","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12]]}}}